In a nutshell This trial looked at the long-term effectiveness and safety of ixazomib (Ixa; Ninlaro) in combination with lenalidomide (R; Revlimid), and dexamethasone (d; Decadron) for the treatment of relapsed/refractory (RR) multiple myeloma (MM). The authors found that there was an improved survival with Ixa-Rd...
Read More
In a nutshell This study investigated the effects of adding ixazomib (Ninlaro) to lenalidomide (Revlimid) and dexamethasone (Dexasone) for patients with unresponsive multiple myeloma. The main finding was that patients receiving ixazomib plus lenalidomide and dexamethasone survived longer without worsening of cancer (progression-free...
Read More
In a nutshell This study examined the safety and effectiveness of ixazomib (Ninlaro) when added to the treatment of relapsed multiple myeloma. Researchers concluded that ixazomib was safe and effective at improving treatment outcomes for relapsed multiple myeloma. Some background The addition of biologic drugs to standard treatment regimens for...
Read More
